


Supplementary Material

Supplementary Methods

Adoptive transfer experiments


Cell suspensions were prepared from pooled spleens and lymph nodes of NZB/WF1 mice without nephritis. T cells were enriched by negative selection using MACS microbeads (Miltenyi Biotech) and stained with CFDA-SE (CFSE) (ThermoFisher). 2.5×10^6 labelled cells were adoptively transferred into healthy (14 week old) or nephritic NZB/WF1 animals. 24 hours later, recipient mice were sacrificed for collection of kidneys to determine the frequencies of transferred CFSE⁺ CD4⁺ and CD8⁺ T cells by flow cytometry.

Supplementary Figures

**Supplementary Figure 1. Impact of dietary fiber on lupus pathology in MRL/*lpr* mice**


(A) Overall survival (OS) determined in lupus-prone MRL/*lpr* mice fed a high (HF; n=12) or low fiber (LF; n=13) diet. The Kaplan-Meier method was used for estimating OS in differently treated groups.

(B) Measurement of anti-dsDNA-IgG serum titers in 20w old animals fed a HF (n=9 mice) or LF (n=8 mice) diet. Results are expressed as scatter blots with mean \pm SEM; each data point represents an individual mouse; $p < 0.05$ was considered significant, $p > 0.2$ is indicated as *ns*, not significant.




Supplementary Figure 2. Lymphoproliferation in progressing disease

(A) Spleen weights and total splenocyte counts in 14w old NZB/WF1 mice (healthy, n=9-10 mice) versus mice with established nephritis (nephritic, n=9-10 mice) fed a normal chow. (B) Total splenocyte counts in 14w (n HF=15 mice, n LF=15 mice) versus 28w (n HF=17 mice, n LF=19 mice) old NZB/WF1 mice fed a HF- versus LF-diet; spleen weights of 14w old NZB/WF1 mice fed a HF- versus LF-diet (n HF=15 mice, n LF=15 mice). Results are expressed as scatter blots with mean \pm SEM; each data point represents an individual mouse; $p < 0.05$ was considered significant, $p > 0.2$ is indicated as *ns*, not significant.




Supplementary Figure 3. Susceptibility to apoptosis and migration of CD4⁺ and CD8⁺ T cells into inflamed and non-inflamed kidneys

(A) Annexin V-binding was examined in spleen CD4⁺ and CD8⁺ T cells from healthy (14w old, n=5 mice) versus nephritic NZB/WF1 animals (n=4 mice). (B) Number of CFSE-labelled CD4⁺ and CD8⁺ T cells, recovered from one kidney of healthy (14w old, n=5 mice) versus nephritic NZB/WF1 animals (n=4 mice) 24h after adoptive transfer. Results are expressed as scatter blots with mean \pm SEM; each data point represents an individual mouse; $p < 0.05$ was considered significant, $p > 0.2$ is indicated as *ns*, not significant.




Supplementary Figure 4. Co-expression of CD44 and IFN γ in CD4 and CD8 T cells

Co-expression of CD44 and IFN γ in CD4⁺ and CD8⁺ T cells of 28w old NZB/WF1 mice by flow cytometry. Shown are representative FACS blots from spleen.



Supplementary Figure 5. Gating strategy for immune status evaluation (innate immune cells)

(A, B) After FSC/SSC-based selection of live leukocytes and exclusion of doublets, CD45⁺ organ-infiltrating neutrophils were selected. Shown are representative FACS blots from spleen (A) and kidney (B). (C) To determine frequencies of main innate immune cell populations, CD45⁺CD19⁻TCRβ⁻NK1.1⁻ were selected and among those cDCs identified as CD11c^{hi}, pDCs as PDCA1^{hi} cells. Monocytic cells were identified as CD11c^{int/-}PDCA1^{int/-}CD11b⁺Ly6G⁻, neutrophils as CD11c^{int/-}PDCA1^{int/-}CD11b⁺Ly6G^{hi} cells. Shown are representative FACS blots from spleen. (D) The expression of the co-stimulatory molecules CD86 or CD80 was quantified on monocytic cells (shown) or cDC (not shown).



Supplementary Figure 6. Gating strategy for immune status evaluation (adaptive immune cells)

(A) After FSC/SSC-based selection of live leukocytes, doublets were excluded. (B) Plasma cells were identified as CD138^{hi}κ/λLC⁺ cells from single cells. (C, D) From single cells, B cells were selected as TCRβ⁺B220⁺ cells (C), CD4⁺ T cells as B220⁺TCRβ⁺CD8⁺CD4⁺ (C, D) and CD8⁺ T cells as B220⁺TCRβ⁺CD4⁺CD8⁺ T cells (C, D). Further determined was the percentage of GL7^{hi}Fas^{hi} GC B cells, CD21^{hi}CD23^{lo} MZ B cells and CD21^{lo}CD23^{hi} follicular B cells on whole B cells (C). Determined was also the % expression of CD44^{hi}, IL-10, IFNγ, IL-17, CXCR5^{hi}PD1^{hi} T_{FH}, FoxP3⁺ T_{reg} and CD103⁺/FoxP3⁺ effector T_{reg} on whole CD4⁺ T cells (D). Shown are representative FACS blots from spleen.

Supplementary Tables

Supplementary Table 1. Immune status in HF- versus LF-fed NZB/WF1 animals

	14w			28w			sick		
	HF	LF		HF	LF		HF	LF	
spleen	mean +/- SEM	mean +/- SEM	p- value	mean +/- SEM	mean +/- SEM	p- value	mean +/- SEM	mean +/- SEM	p- value
CD11b ⁺ Ly6G ^{hi} neutrophils/live cells	0.1253 0.03651	0.1113 0.0155	<i>ns</i>	0.351 0.08532	0.303 0.07805	<i>ns</i>	0.3571 0.09329	0.4771 0.1194	<i>ns</i>
CD11c ^{hi} eDC/ live cells	0.08 0.004629	0.104 0.01166	<i>0.0927</i>	0.1183 0.0339	0.1882 0.01267	<i>ns</i>	0.2105 0.01495	0.5529 0.1055	<i>0.0012</i>
CD80 ⁺ /cDC	84.92 1.445	85.53 1.413	<i>ns</i>	76.72 4.262	70.68 2.397	<i>0.0555</i>	62.14 6.456	49.6 5.382	<i>0.1014</i>
CD86 ⁺ /cDC	10.02 2.911	10.16 2.544	<i>ns</i>	7.268 0.5572	9.903 0.5193	<i>0.0027</i>	20.81 1.166	16.81 2.078	<i>0.1282</i>
PDCA1 ^{hi} pDC/live cells	0.161 0.02822	0.228 0.03878	<i>0.1474</i>	0.2203 0.02802	0.1419 0.02065	<i>0.011</i>	0.06571 0.01798	0.09143 0.01738	<i>0.2145</i>
Ly6G ⁺ CD11b ⁺ monocytic cells/ live cells	2.557 0.3946	2.215 0.4646	<i>ns</i>	1.332 0.06755	1.144 0.04852	<i>0.0275</i>	1.076 0.2253	1.373 0.2865	<i>ns</i>
CD80 ⁺ /monocytic cells	44.09 4.473	38.82 4.055	<i>ns</i>	45.71 1.94	39.46 0.9389	<i>0.0065</i>	57.3 6.623	47.46 7.409	<i>ns</i>
CD86 ⁺ /monocytic cells	4.343 1.2	4.295 1.003	<i>ns</i>	10.88 0.8417	11.43 0.5225	<i>0.1312</i>	10.77 1.642	14.72 1.546	<i>0.0973</i>
TCRβ ⁺ CD4 ⁺ T cells/live cells	24.06 1.309	23.87 1.035	<i>ns</i>	24.84 1.156	19.86 0.9716	<i>0.0035</i>	20.96 1.392	21.28 1.85	<i>ns</i>
CD44 ^{hi} /CD4 ⁺ T cells	12.2 0.7192	12.88 1.539	<i>ns</i>	36.74 3.092	59.19 3.877	<i><0.0001</i>	56.67 7.282	72.4 2.204	<i>0.0175</i>
CXCR5 ^{hi} PD1 ^{hi} /CD4 ⁺ T cells (T _{H1})	0.48 0.07974	0.3575 0.03245	<i>ns</i>	2.884 0.3821	5.516 0.5991	<i>0.0015</i>	4.689 1.265	9.744 2.265	<i>0.0565</i>
IFNγ ⁺ /CD4 ⁺ T cells	3.164 0.79	3.462 0.7842	<i>ns</i>	12.12 1.38	16.66 1.333	<i>0.02</i>	25.24 3.477	29.88 3.421	<i>ns</i>
IL-17 ⁺ /CD4 ⁺ T cells	0.232 0.04283	0.11 0.03017	<i>0.0556</i>	0.4123 0.06362	0.4 0.07092	<i>0.6239</i>	0.26 0.05	0.1957 0.03644	<i>ns</i>
IL-10 ⁺ /CD4 ⁺ T cells	0.25 0.07993	0.212 0.05551	<i>ns</i>	3.373 0.4721	6.759 0.7053	<i>0.0003</i>	8.999 1.429	13.78 1.438	<i>0.0379</i>
FoxP3 ⁺ /CD4 ⁺ T cells (T _{reg})	14.38 1.766	13.24 0.595	<i>ns</i>	20.75 1.267	28.15 1.272	<i>0.0007</i>	22.3 2.121	27.64 1.233	<i>0.0787</i>
CD103 ⁺ /FoxP3 ⁺ CD4 ⁺ T cells (effector T _{reg})	13.63 0.588	14.32 1.196	<i>ns</i>	25.15 1.667	34.92 2.261	<i>0.0024</i>	38.94 3.945	53.05 0.74	<i>0.0111</i>
TCRβ ⁺ CD8 ⁺ T cells/live cells	18.29 1.635	16.65 1.601	<i>ns</i>	14.47 0.9333	9.967 0.967	<i>0.0028</i>	5.325 0.5426	2.203 0.3542	<i>0.0012</i>
CD44 ^{hi} /CD8 ⁺ T cells	4.622 0.5405	3.594 0.3901	<i>0.1903</i>	13.66 0.9019	22.6 2.334	<i>0.0024</i>	10.42 1.638	21.83 2.107	<i>0.0070</i>
IFNγ ⁺ /CD8 ⁺ T cells	12.9 1.776	12.47 2.523	<i>ns</i>	13.94 1.038	12.2 0.9123	<i>0.3081</i>	27.1 5.769	47.36 4.412	<i>0.0221</i>
TCRβ ⁺ B220 ⁺ B cells/live cells	44.11 2.898	56.83 9.722	<i>0.0952</i>	43.47 1.735	44.87 1.678	<i>ns</i>	46.57 2.872	40.04 5.356	<i>ns</i>
Fas ^{hi} GL7 ^{hi} /B cells	0.4888 0.09563	0.5225 0.09955	<i>ns</i>	1.423 0.2986	2.33 0.3123	<i>ns</i>	4.545 0.4609	4.694 0.408	<i>0.6163</i>
CD21 ^{lo} CD23 ^{hi} (follicular)/ B cells	61.57 3.494	54.18 4.653	<i>ns</i>	61.73 0.7922	57.04 1.387	<i>0.0118</i>	48.43 5.979	52.62 1.744	<i>ns</i>
CD21 ^{hi} CD23 ^{lo} (MZ)/B cells	13.48 1.379	13.97 0.8889	<i>0.8205</i>	11.55 1.352	11.02 1.24	<i>ns</i>	4.334 1.609	0.7443 0.2154	<i>ns</i>
LC ⁺ CD138 ^{hi} /live cells (plasma cells)	1.062 0.1252	0.742 0.1155	<i>0.0601</i>	2.184 0.2187	2.469 0.1813	<i>ns</i>	2.091 0.3969	2.023 0.2869	<i>ns</i>
kidney									
CD45 ⁺ /live cells	10.26 1.127	14 1.396	<i>0.0393</i>	20.8 4.249	29.48 4.42	<i>0.1084</i>	68.72 5.191	76.49 1.447	<i>ns</i>
CD11b ⁺ Ly6G ^{hi} neutrophils/CD45 ⁺ cells	3.722 1.133	2.735 0.6107	<i>ns</i>	1.775 0.293	1.015 0.1645	<i>0.0377</i>	1.204 0.3188	1.103 0.3165	<i>ns</i>
CD11c ^{hi} eDC/CD45 ⁺ cells	1.36 0.09663	1.585 0.1143	<i>ns</i>	0.3234 0.03083	0.3564 0.04198	<i>ns</i>	1.513 0.4775	1.249 0.2478	<i>ns</i>
PDCA1 ^{hi} pDC/CD45 ⁺ cells	0.8036 0.102	0.9069 0.08902	<i>ns</i>	0.4135 0.0401	0.3356 0.05396	<i>0.0663</i>	0.07333 0.03029	0.1371 0.02523	<i>0.1270</i>
CD11b ⁺ monocytic cells/CD45 ⁺ cells	19.95 3.03	24.87 3.36	<i>ns</i>	15.42 1.383	10.41 0.8231	<i>0.0086</i>	12.27 1.103	13.71 2.44	<i>ns</i>
TCRβ ⁺ CD4 ⁺ T cells/CD45 ⁺ cells	19.72 1.642	22.79 0.9714	<i>0.1656</i>	30.87 1.961	35.78 1.347	<i>0.0486</i>	33.05 2.36	35.77 1.341	<i>ns</i>
CD44 ^{hi} /CD4 ⁺ T cells	14.2 1.31	12.78 1.29	<i>0.1447</i>	39.73 3.209	47.88 4.619	<i>0.3147</i>	21.68 1.448	20.37 1.009	<i>ns</i>
IFNγ ⁺ /CD4 ⁺ T cells	3.921 0.6832	5.964 0.8176	<i>0.0439</i>	23.85 3.66	13.42 1.758	<i>0.0439</i>	17.91 2.753	13.58 2.112	<i>ns</i>
FoxP3 ⁺ /CD4 ⁺ T cells (T _{reg})	14.85	13.71	<i>ns</i>	15.13	17.62	<i>0.037</i>	19.06	19.29	<i>ns</i>

Supplementary Material

	1.112	1.169		0.5649	0.8359		0.32	1.319	
CD103 ⁺ FoxP3 ⁺ /CD4 ⁺ T cells	22.19	24.92	<i>ns</i>	22.57	24.67	<i>0.2711</i>	25.44	39.22	<i>0.0175</i>
(effector T _{reg})	1.882	1.891		1.353	1.357		2.889	3.297	
TCRβ ⁺ CD8 ⁺ T cells/CD45 ⁺ cells	9.799	8.852	<i>0.1086</i>	11.48	18.12	<i>< 0.0001</i>	23.11	23.83	<i>ns</i>
	0.848	0.9873		0.7375	0.9958		2.951	3.701	
CD44 ^{hi} /CD8 ⁺ T cells	3.958	3.197	<i>0.1112</i>	16.68	25.19	<i>0.3342</i>	17.33	11.39	<i>0.1649</i>
	0.4138	0.2133		2.914	4.392		2.619	2.708	
IFNγ ⁺ /CD8 ⁺ T cells	7.755	12.36	<i>0.0688</i>	16.05	14.59	<i>ns</i>	26.66	31.15	<i>ns</i>
	1.405	2.025		1.3071	1.391		4.321	8.403	
TCRβ ⁺ B220 ⁺ B cells/CD45 ⁺ cells	13.53	11.45	<i>ns</i>	11.53	10.76	<i>ns</i>	8.344	9.524	<i>ns</i>
	1.938	1.27		0.7848	1.169		1.205	0.82	

Broad immune status evaluation in spleen and kidney of HF- and LF-treated NZB/WF1 mice by FACS at 14w (yet healthy animals; n HF/LF=10-15 mice), at 28w (animals with established autoantibodies but no signs of overt nephritis; n HF=11-17 mice, n LF=14-19 mice) and in nephritic animals (n HF/LF=7 mice). Results are expressed as mean +/- SEM; $p < 0.05$ was considered significant, $p > 0.2$ is indicated as *ns*, not significant.

Supplementary Table 2. Immune status in healthy and nephritic NZB/WF1 animals

	healthy	nephritic	
spleen	mean +/- SEM	mean +/- SEM	p- value
CD11b ⁺ Ly6G ^{hi} neutrophils/live cells	0.1586 0.06162	0.4425 0.09821	0.0275
CD11c ^{hi} cDC/ live cells	0.09 0.01215	0.325 0.04372	<0.0001
CD80 ⁺ /cDC	85.5 1.182	55.66 3.795	<0.0001
CD86 ⁺ /cDC	15.78 2.449	20.64 1.655	0.1422
PDCA1 ^{hi} pDC/live cells	0.18 0.01215	0.07818 0.0122	0.0005
Ly6G ⁺ CD11b ⁺ monocytic cells/ live cells	1.657 0.4879	1.431 0.2542	ns
CD80 ⁺ /monocytic cells	47.33 4.1	54.43 3.169	ns
CD86 ⁺ /monocytic cells	6.986 0.4731	11.47 1.017	0.0019
TCRβ ⁺ CD4 ⁺ T cells/live cells	23.37 1.446	19.33 1.339	0.0683
CD44 ^{hi} /CD4 ⁺ T cells	9.294 0.4639	71.1 2.299	<0.0001
CXCR5 ^{hi} PD1 ^{hi} /CD4 ⁺ T cells (T _{HH})	0.3743 0.01251	6.92 0.9928	<0.0001
IFNγ ⁺ /CD4 ⁺ T cells	3.489 0.4959	24.55 2.963	<0.0001
IL-17 ⁺ /CD4 ⁺ T cells	0.3057 0.07606	0.1508 0.02013	0.1146
IL-10 ⁺ /CD4 ⁺ T cells	0.3557 0.05851	11.77 1.191	<0.0001
FoxP3 ⁺ /CD4 ⁺ T cells (T _{reg})	14.63 1.115	25.49 0.7015	<0.0001
CD103 ⁺ /FoxP3 ⁺ CD4 ⁺ T cells (effector T _{reg})	12.1 1.391	49.92 2.208	<0.0001
TCRβ ⁺ CD8 ⁺ T cells/live cells	19.65 0.7801	3.564 0.4562	<0.0001
CD44 ^{hi} /CD8 ⁺ T cells	3.19 0.2959	13.67 1.388	0.0001
IFNγ ⁺ /CD8 ⁺ T cells	9.184 0.5472	42.35 3.74	<0.0001
TCRβ ⁺ B220 ⁺ B cells/live cells	45.85 1.136	43.07 3.741	ns
Fas ^{hi} GL7 ^{hi} /B cells	0.4771 0.1386	2.248 0.3478	0.0002
CD21 ^{lo} CD23 ^{hi} (follicular)/ B cells	62.11 3.057	43 4.795	0.0221
CD21 ^{hi} CD23 ^{lo} (MZ)/B cells	9.281 1.545	2.643 0.6124	0.0007
LC ⁺ CD138 ^{hi} /live cells (plasma cells)	0.6714 0.06382	2.451 0.454	0.0098
kidney			
CD45 ⁺ /live cells	26 3.411	75.34 1.955	<0.0001
CD11b ⁺ Ly6G ^{hi} neutrophils/CD45 ⁺ cells	4.503 1.291	0.7033 0.09037	0.1361
CD11c ^{hi} cDC/CD45 ⁺ cells	1.483 0.1407	1.14 0.1795	0.1609
PDCA1 ^{hi} pDC/CD45 ⁺ cells	0.7814 0.1154	0.1383 0.0286	<0.0001
CD11b ⁺ monocytic cells/CD45 ⁺ cells	23.32 4.776	13.56 0.9018	0.1422
TCRβ ⁺ CD4 ⁺ T cells/CD45 ⁺ cells	25.13 1.988	31.34 1.399	0.0358
CD44 ^{hi} /CD4 ⁺ T cells	7.344 0.4249	20.4 1.02	<0.0001
IFNγ ⁺ /CD4 ⁺ T cells	4.317 0.6084	17.1 3.329	0.0221
FoxP3 ⁺ /CD4 ⁺ T cells (T _{reg})	14.14 1.128	19.47 1	0.0052
CD103 ⁺ FoxP3 ⁺ /CD4 ⁺ T cells (effector T _{reg})	17.42 1.009	29.5 2.95	0.0037
TCRβ ⁺ CD8 ⁺ T cells/CD45 ⁺ cells	8.73 0.6389	30.14 1.84	<0.0001

Supplementary Material

CD44 ^{hi} /CD8 ⁺ T cells	3.643	14.76	0.0018
	0.911	2.88	
IFN γ ⁺ /CD8 ⁺ T cells	12.95	28.13	0.0831
	4.612	5.358	
TCR β ⁺ B220 ⁺ B cells/CD45 ⁺ cells	12.32	8.646	0.0866
	1.776	1.173	

Broad immune status evaluation in spleen and kidney of 14w old, yet healthy and nephritic animals fed a normal chow (n healthy=7-9 mice, n nephritic=10-12 mice). Results are expressed as mean \pm SEM; $p < 0.05$ was considered significant, $p > 0.2$ is indicated as *ns*, *not significant*.

Supplementary Table 3. Patient's and healthy control's characteristics

	HC	SLE	SLE subgroup
total number	67	86	29
females	60	71	27
males	7	15	2
age (years)			
median	46	48	52
range	18-64	19 - 83	19-82
BMI (kg/m²)			
median	29,3	24.5	25,6
range	18,5-65	16,1 - 47,2	18,6-47,2
Leptin (pg/ml)			
median	18.75	9,07	12,3
range	2,09-55,28	0,36-44,67	1,8-42,5
CRP (mg/l)			
median	3	3	3
range	3-28,8	3-33,5	3,0-29
LPS (pg/ml)			
median	2.56	2.58	1.3
range	0-19.78	0-23.22	0-12.05
SLEDAI			
median	/	2	1
range	/	0 - 23	0-2
%HLA-DR/CD3⁺ T cells			
median	5,7	8,96	9
range	1,25-12,2	1,63-41,42	4-34,7
%HLA-DR/CD4⁺ T cells			
median	3,68	6	5,9
range	1,52-9,22	1,27-26,93	21-26,9
%HLA-DR/CD8⁺ T cells			
median	13,96	18,51	21,3
range	2,71-34,8	2,9-69,01	2,9-54,9

Supplementary Material

Depicted are total numbers of subjects divided by male and female, median (+ range) age (years), BMI (kg/m²), serum levels of leptin (pg/ml), CRP (mg/l), LPS (pg/ml), SLEDAI and % HLA-DR expression on CD3⁺, CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells. HC=healthy controls, SLE=all enrolled SLE patients, SLE subgroup=defined group of SLE patients with SLEDAI \leq 2, receiving a treatment of no more than hydroxychloroquine/chloroquine, prednisone \leq 5mg and no DMARDs/biologicals.

Supplementary Table 4. Patient's characteristics

	all	steroids (prednisone)			treatment				
					no DMARD				
					no biological	HCQ/CQ	DMARD	biological	DMARD + biological
		no steroids	≤ 5mg	> 5mg	no HCQ/CQ	mono	(+/- HCQ/CQ)	(+/- HCQ/CQ)	(+/- HCQ/CQ)
SLEDAI									
<i>median</i>	2	2	4	6	0	2	4	3	2
<i>range</i>	0 - 23	0-18	0-23	0-16	0-4	0-6	0-23	0-8	0-12
treatment									
<i>no DMARD/biological/HCQ/CQ</i>	8	5	1	1					
<i>HCQ/CQ mono</i>	30	25	4	1					
<i>DMARD (+/- HCQ/CQ)</i>	29	14	9	6					
<i>biological (+/- HCQ/CQ)</i>	5	2	3	1					
<i>DMARD + biological (+/- HCQ/CQ)</i>	13	3	9	2					
steroids (prednisone)									
<i>no steroids</i>	49				5	25	14	1	3
<i>≤ 5mg</i>	25				1	4	9	3	8
<i>> 5mg</i>	11				2	1	6	1	2
	all	SLEDAI							
		0	1 - 4	5 - 8	> 8				
treatment									
<i>no DMARD/biological/HCQ/CQ</i>	8	5	3	0	0				
<i>HCQ/CQ mono</i>	31	10	17	3	0				
<i>DMARD (+/- HCQ/CQ)</i>	29	10	11	3	5				
<i>biological (+/- HCQ/CQ)</i>	5	1	3	1	0				
<i>DMARD + biological (+/- HCQ/CQ)</i>	13	4	7	1	2				
steroids (prednisone)									
<i>no steroids</i>	50	8	18	6	5				
<i>≤ 5mg</i>	25	6	16	2	2				
<i>> 5mg</i>	11	2	2	4	3				

Tabular list of the different treatments of all SLE patients enrolled (above). Indicated is also the median SLEDAI in relation to the different treatment groups. Indicated are the different treatments within groups of patients with a SLEDAI of 0, 1-4, 5-8 or >8 (below).

Supplementary Table 5. Immune status in NZB/WF1 animals treated with SCFA

	SCFA	untreated	
spleen	mean +/- SEM	mean +/- SEM	p- value
CD11b ⁺ Ly6G ^{hi} neutrophils/live cells	0.1674 0.02529	0.1588 0.02049	<i>ns</i>
CD11c ^{hi} cDC/ live cells	0.4175 0.05334	0.3323 0.04009	<i>ns</i>
PDCA1 ^{hi} pDC/ live cells	0.4753 0.03136	0.4566 0.0275	<i>ns</i>
Ly6G ⁺ CD11b ⁺ monocytic cells/ live cells	1.148 0.1718	0.9448 0.134	<i>ns</i>
TCRβ ⁺ CD4 ⁺ T cells/live cells	21.08 0.8633	23.04 0.8088	<i>ns</i>
CD44 ^{hi} /CD4 ⁺ T cells	39.09 3.408	33.32 2.173	<i>ns</i>
CXCR5 ^{hi} PD1 ^{hi} /CD4 ⁺ T cells (T _{FH})	3.353 0.519	2.584 0.4024	<i>ns</i>
IFNγ ⁺ /CD4 ⁺ T cells	9.533 1.662	7.104 0.8536	<i>ns</i>
IL-17 ⁺ /CD4 ⁺ T cells	0.116 0.01262	0.1285 0.01435	<i>ns</i>
IL-10 ⁺ /CD4 ⁺ T cells	4.941 0.7694	3.152 0.3412	<i>ns</i>
FoxP3 ⁺ /CD4 ⁺ T cells (T _{reg})	24.09 1.325	20.57 0.9151	<i>0.1698</i>
CD103 ⁺ /FoxP3 ⁺ CD4 ⁺ T cells (effector T _{reg})	31.81 1.588	26.06 0.9389	<i>0.0234</i>
TCRβ ⁺ CD8 ⁺ T cells/live cells	10.3 0.7499	11.51 0.7722	<i>ns</i>
CD44 ^{hi} /CD8 ⁺ T cells	16.21 1.126	14.13 0.7025	<i>ns</i>
IFNγ ⁺ /CD8 ⁺ T cells	9.476 1.528	7.533 1.054	<i>ns</i>
TCRβ ⁺ B220 ⁺ B cells/live cells	44.226921 1.4951014	42.471733 1.2215557	<i>ns</i>
Fas ^{hi} GL7 ^{hi} /B cells	2.736 0.3123	2.246 0.1868	<i>ns</i>
CD21 ^{lo} CD23 ^{hi} (follicular)/B cells	55.64 1.961	54.09 1.161	<i>ns</i>
CD21 ^{hi} CD23 ^{lo} (MZ)/B cells	18.09 1.621	21.09 1.115	<i>ns</i>
LC ⁺ CD138 ^{hi} /live cells	2.976 0.3941	2.736 0.233	<i>ns</i>
kidney			
CD45 ⁺ /live cells	11.73 1.227	10.91 1.002	<i>ns</i>
CD11b ⁺ Ly6G ^{hi} neutrophils/CD45 ⁺ cells	1.046 0.1392	1.014 0.1299	<i>ns</i>
CD11c ^{hi} cDC/CD45 ⁺ cells	0.9627 0.1156	1.077 0.1518	<i>ns</i>
PDCA1 ^{hi} pDC/CD45 ⁺ cells	0.2533 0.0258	0.3589 0.04507	<i>0.1620</i>
CD11b ⁺ monocytic cells/CD45 ⁺ cells	7.164 0.826	6.24 0.5791	<i>ns</i>
TCRβ ⁺ CD4 ⁺ T cells/live cells	40.03 1.074	42.12 1.621	<i>ns</i>
CD44 ^{hi} /CD4 ⁺ T cells	53.23 4.275	47.22 2.871	<i>ns</i>
IFNγ ⁺ /CD4 ⁺ T cells	7.985 2.119	8.467 1.636	<i>ns</i>
FoxP3 ⁺ /CD4 ⁺ T cells (T _{reg})	17.23 0.9731	17.11 0.8044	<i>ns</i>
CD103 ⁺ FoxP3 ⁺ /CD4 ⁺ T cells (effector T _{reg})	25.61 1.495	17.31 1.511	<i>0.0041</i>
TCRβ ⁺ CD8 ⁺ T cells/CD45 ⁺ cells	16.89 0.7899	16.19 0.5346	<i>ns</i>
CD44 ^{hi} /CD8 ⁺ T cells	44.19 5.308	36.23 3.027	<i>ns</i>
IFNγ ⁺ /CD8 ⁺ T cells	7.467 1.264	8.34 1.188	<i>ns</i>
TCRβ ⁺ B220 ⁺ B cells/CD45 ⁺ cells	18.21 1.731	15.89 1.147	<i>ns</i>

Supplementary Material

Broad immune status evaluation in spleen and kidney of 28w old NZB/WF1 mice, receiving a SCFA-mix or untreated drinking water (n SCFA=10-18 mice and n untreated=10-19 mice). Results are expressed as mean +/- SEM; $p < 0.05$ was considered significant, $p > 0.2$ is indicated as *ns*, *not significant*.